截至2025年8月25日收盘，乐普医疗股价报20.62元，较前一交易日上涨2.46元。当日成交量为120.27万 手，成交金额达24.41亿元，换手率为7.44%。 乐普医疗是一家专注于心血管疾病领域全生命周期整体解决方案的医疗企业。公司主营业务涵盖医疗器 械、药品、医疗服务及健康管理三大板块，产品线包括心血管植介入器械、人工智能生命指征监测设备 等。根据最新财报显示，公司2025年上半年实现营业收入33.69亿元，扣非净利润6.62亿元，同比增长 2.33%。 从资金流向来看，8月25日乐普医疗主力资金净流出7679.15万元，近五日累计净流出2.68亿元。公司当 前总市值387.78亿元，流通市值333.24亿元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 来源：金融界 公司近期在创新产品研发方面取得多项进展。上半年新获批产品包括冠脉棘突球囊扩张导管 Vessridge®、紫杉醇涂层外周球囊扩张导管DilatBK等心血管植介入产品。创新药研发方面，GLP- 1/GCG/GIP受体三重激动剂候选药物MWN101已完成二期临床试验。在国际化布局上，公司产品已进入 全球160多个国家 ...

Group 1 - The core viewpoint of the article highlights the financial performance of Lepu Medical in the first half of 2025, showing a slight decline in revenue and net profit, but an increase in cash flow from operating activities [1] - Lepu Medical achieved operating revenue of 3.369 billion yuan, a year-on-year decrease of 0.43% [1] - The net profit attributable to shareholders was 691 million yuan, down 0.91% year-on-year, while the net profit excluding non-recurring gains and losses was 662 million yuan, up 2.33% year-on-year [1] - The net cash flow from operating activities reached 636 million yuan, reflecting a significant increase of 300.52% [1] Group 2 - In terms of innovation, Lepu Medical's cardiovascular interventional product matrix is expected to contribute to revenue and profit growth, with several new products approved in the first half of the year [1] - Key new products include the Vessridge® coronary balloon dilation catheter, DilatBK™ paclitaxel-coated peripheral balloon dilation catheter, PeVaDilat™ drug-coated peripheral balloon dilation catheter, and FireZip® RF ablation device [1] - The company’s innovative drug subsidiary, Shanghai Minwei Biotechnology, has completed Phase II clinical trials for its GLP1/GCG/GIP receptor triple agonist candidate MWN101, marking a significant milestone in obesity and type 2 diabetes treatment [2] - Lepu Medical is advancing its consumer healthcare products in ophthalmology and dermatology, with new products approved for market [2] - The company has established marketing channels in over 160 countries and regions, with 341 product registrations covering various fields, demonstrating its commitment to internationalization [2]